Related Experiment Videos
[Inhalation of nitric oxide - dependence: case report]
W B Carvalho1, T Matsumoto, S M Horita
1Universidade Federal de São Paulo, SP, Brazil.
Jornal De Pediatria
|December 4, 2003
Summary
Pulmonary hypertension rebound can occur after stopping inhaled nitric oxide (NO) treatment in pediatric acute respiratory distress syndrome (ARDS) patients. Careful monitoring is crucial during NO withdrawal to manage potential hemodynamic instability.
Area of Science:
- Pediatric Critical Care Medicine
- Cardiovascular Physiology
Background:
- Acute respiratory distress syndrome (ARDS) can lead to pulmonary hypertension.
- Inhaled nitric oxide (NO) is used to treat pulmonary hypertension in ARDS.
- The potential for rebound pulmonary hypertension after NO withdrawal is a clinical concern.
Purpose of the Study:
- To describe the hemodynamic response, specifically pulmonary hypertension rebound, after inhaled NO withdrawal in a pediatric ARDS patient.
- To highlight the clinical implications of managing inhaled NO therapy in this population.
Main Methods:
- A case report detailing a pediatric patient with ARDS and pulmonary hypertension.
- Echocardiography with Doppler was used to monitor pulmonary artery pressure (PAP).
- Inhaled NO was administered for 21 days, with periods of withdrawal and reintroduction.
Main Results:
- Inhaled NO titration initially reduced PAP from 52 mmHg to 44 mmHg.
- Withdrawal of inhaled NO led to a PAP increase to 55 mmHg, requiring reintroduction.
- A subsequent attempt at withdrawal after 20 days of treatment caused clinical worsening and increased PAP.
Conclusions:
- Rebound pulmonary hypertension is a potential complication following inhaled NO withdrawal in pediatric ARDS.
- Prolonged inhaled NO treatment necessitates careful consideration of withdrawal protocols.
- This case underscores the importance of vigilant monitoring for hemodynamic changes during inhaled NO discontinuation.